Changes in Hong Kong stocks | Rebon Pharmaceutical-B (09637) rose more than 10% in early trading, partner r1 presented the AP306 global phase IIb multi-regional clinical trial design poster at ASN Kidney Week

The Zhitong Finance App learned that Rebang Pharmaceutical-B (09637) rose more than 10% in early trading. As of press release, it rose 8.21% to HK$17.26, with a turnover of HK$108.661 million.

According to the news, Rebon Pharmaceuticals announced that the company's partner R1 presented the study design for a global phase IIb multi-regional clinical trial (NCT06712654) for hyperphosphatemia patients undergoing maintenance hemodialysis at the 2026 American Society of Nephrology Kidney Week (ASN Kidney Week 2026) in the form of a trial-in-progress (trial-in-progress) poster.

This global phase IIb multi-regional clinical trial was co-sponsored by Rebon Pharmaceuticals and R1, and is currently being carried out at various clinical centers in the US and China. On July 21, 2026, the company announced that the trial had completed the randomization and administration of the first test. Currently, the recruitment of subjects for clinical centers in the US and China is ongoing. The trial is expected to be completed in the second quarter of 2027, and the top-line data will be announced in due course.